Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: biphasic insulin aspart 30

Study type: Observational

Funder types: Industry

Identifiers

NCT01565733

BIASP-4017

Details and patient eligibility

About

This study is conducted in Europe. The aim of this study is to evaluate the safety and efficacy of biphasic insulin aspart (NovoMix® 30) in hospitalised patients with type 2 diabetes with the aim of intensifying their treatment.

Enrollment: 2,223 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with type 2 diabetes
• Treated with oral anti-diabetics and/or human insulin

Exclusion criteria

• Persons previously included in the trial
• Hypersensitive to biphasic insulin aspart or any of the excipients
• Pregnant or lactating women, or those who plan to get pregnant within the next 12 months

Trial design

2,223 participants in 1 patient group

NovoMix® 30 users

Treatment:

Drug: biphasic insulin aspart 30